ix. Figure legends
FIGURE 1. Patient flow through the study.
FIGURE 2. Levels of sIgE concentrations for nut-specific
storage proteins Ana o3 / Ara h2 for cashew nut and peanut
allergic patients undergoing OIT. Values >100 kU/L were set
to 120 kU/L.
FIGURE 3. A Severity of allergic reactions during OIT by nut
allergy graded by oFASS-5.
B Severity of side effects during OIT by nut allergy and
separated by presence of other food allergies.C Heatmap of the severity of reaction during OIT (mild: oFASS
0-1; moderate: oFASS 2-3; severe: oFASS 4-5) in relation to the initial
levels of sIgE against storage proteins (Ana o3, Ara h2).
FIGURE 4. Cumulative incidence curves for reaching maintenance
dose in patients (A) undergoing therapy in the cashew nut
(N=24) and the peanut (N=38) group, (B) with (N=31) and without
asthma (N=31), (C) with (N=33) and without (N=29) other food
allergy, 1) representing the patients who reached the maintenance dose
(continuous lines), 2) the group of patients who were defined as
drop-outs (n=11) (dashed lines). Dotted line represents median time to
reaching maintenance dose.
FIGURE 5. A Changes of sIgE for the storage protein (Ana o3/Ara
h2) from t0 (=before starting the OIT) to t1 (=reaching maintenance
dose). Available data for cashew nut (n=19) and peanut (n=25).
B Progression over time of sIgE’s for the storage protein (Ana
o3/Ara h2) for the patients who underwent a second OFC (t2) for cashew
nut (n=8) and peanut (n=13). Black lines are representing patients who
had no reaction during the second OFC and were classified as
desensitized, red lines representing patients who failed to complete the
second OFC with an intolerance.
x. Appendices
Supplementary material on OIT starting protocol